VKTX 240816 67.00P (VKTX240816P67000) Stock Options, News & Quotes

US OptionsDetailed Quotes

VKTX240816P67000

Watchlist

11.48
+1.08+10.38%

15min DelayClose Aug 16 16:00 ET

11.50High11.00Low

Intraday

5D
Daily

News

Could Viking Therapeutics Become the Next Novo Nordisk?
Yahoo FinanceAug 17 06:09 ET
Why Is Viking Therapeutics, Inc. (VKTX) the Best Diabetes Stock to Buy Now?
Yahoo FinanceAug 16 21:13 ET
Viking Therapeutics Insider Sold Shares Worth $1,195,736, According to a Recent SEC Filing
MT NewswiresAug 15 03:13 ET
Director J Singleton Sells 20,786 Shares of Viking Therapeutics Inc (VKTX)
InvestingAug 14 19:13 ET
Deutsche Bank praises Eli Lilly and Co (LLY.US) as a "high-growth unicorn", with a target price skyrocketing to $1025.
Deutsche Bank has upgraded its rating on Eli Lilly and Co (LLY.US) from "hold" to "buy" with a target price increase from $725 to $1025.
Zhitong FinanceAug 13 02:52 ET
Buy Russell 1000 Health Care Growth, Says Oppenheimer in Highlighting Top Sector Ideas
Seeking AlphaAug 12 13:48 ET

Comments

Moomoo News Global

Aug 5 07:33

Columns What You Need to Know Ahead of Eli Lilly Q2 Earnings

$Eli Lilly and Co (LLY.US)$ reports earnings before markets open on August 8, with analysts projecting revenue and profits to be boosted by the popularity of the weight-loss drugs Mounjaro and Zepbound.
Eli Lilly shares have risen by more than 38% since the start of the year, closing at $804.46 last Friday, but down from the record level of $996.1 seen earlier this month.
The drugmaker is projected to report $9.99 billion in revenue, a 20% bump ...

iamiam

Jul 26 10:58

$Viking Therapeutics (VKTX.US)$
Hold 70 you bad ass 😍 $Viking Therapeutics (VKTX.US)$
$Viking Therapeutics (VKTX.US)$

Unsupported module. Please view on mobile devices.

joe black8

Jul 26 10:14

Lly instead of losing 100b in cap

$Viking Therapeutics (VKTX.US)$ could have bought this for 20b, what losers

TrendTrader

Jul 26 09:59

70 🎯 hit!

$Viking Therapeutics (VKTX.US)$

BullnBearTrading

Jul 26 04:58

Viking Therapeutics Shares Surge Nearly 40% as Weight Loss Drug Advances, Eli Lilly Loses $120 Billion in Market Value

Shares of Viking Therapeutics soared nearly 40% intraday following discussions with the FDA that accelerated the development of their weight loss candidate VK2735 to phase 3 trials, potentially advancing its market debut by a year. This drug, administered monthly, is anticipated to be more convenient than Eli Lilly and Novo Nordisk's treatments. The oral version of VK2735 will be...